BAAR, Switzerland--(BUSINESS WIRE)--CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow's initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate..

瑞士巴尔——（商业新闻短讯）——CorFlow Therapeutics AG（CorFlow）今天宣布，在Broadview Ventures和Panakes Partners的共同领导下，在415 Capital（CorFlow的初始风险投资方和最大股东）的持续大力支持下，已筹集到4400万欧元的B系列资金。Merieux Equity Partners、Laerdal Million Lifes Fund、Wellington Partners、M＆L Investments、Unorthodox Ventures、KOFA Healthcare和Monte Carlo Capital参与了该跨国财团。。

Concurrent with the financing, David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors.

在融资的同时，Broadview Ventures的David Prim、Panakes Partners的Barbara Castellano、Merieux Equity Partners的Yoann Bonnamour和Laerdal Million Lifes Fund的Rhiya Pau加入了CorFlow董事会。

The Series B will fund the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate CorFlow’s CoFl system to diagnose MVO in heart attack patients immediately following stent implantation. Additionally, it will fund an adaptive platform therapy study evaluating treatment effects of therapeutic agents delivered locally through the CoFl system on heart attack patients diagnosed with MVO..

B系列将资助旨在获得美国市场许可的MOCA II（MVO with CoFITM System Assessment II）关键研究。该试验将在美国和欧洲进行，旨在验证CorFlow的CoFl系统在支架植入后立即诊断心脏病发作患者的MVO。此外，它将资助一项适应性平台治疗研究，评估通过CoFl系统局部递送的治疗剂对诊断为MVO的心脏病发作患者的治疗效果。。

MVO affects more than half of all patients who suffer an acute heart attack and is an independent predictor for heart failure and mortality. Currently not routinely diagnosed MVO remains largely untreated, leading to poor patient outcomes, and contributing to high health care costs associated with cardiovascular disease..

MVO影响超过一半的急性心脏病发作患者，是心力衰竭和死亡率的独立预测因子。目前尚未常规诊断的MVO在很大程度上仍未得到治疗，导致患者预后不佳，并导致与心血管疾病相关的医疗保健费用高昂。。

CorFlow’s CoFl system is being developed to provide timely, accurate and consistent detection of MVO while patients are still in the catheter laboratory (cath lab) immediately following the reopening of the larger epicardial arteries with a stent. Uniquely, the technology has been designed to also enable localized delivery of therapeutics to the microvasculature upon MVO diagnosis.

CorFlow的CoFl系统正在开发中，以在患者用支架重新打开较大的心外膜动脉后立即仍在导管实验室（cath lab）中时，提供及时，准确和一致的MVO检测。独特的是，该技术的设计还可以在MVO诊断时将治疗剂局部递送至微血管。

CoFl also seamlessly integrates into standard workflows utilizing existing guide catheter and wire access..

CoFl还利用现有的引导导管和导线接入无缝集成到标准工作流程中。。

'We are thrilled to have closed on this significant round of financing, backed by a top-tier global syndicate of medical technology investors,' commented Paul Mead, President and Chief Executive Officer of CorFlow. 'Recent data from over 70 patients in our MOCA I first in human trial and from our extensive preclinical program support our collective confidence that we can improve outcomes in patients who suffer heart attacks, specifically those patients whose microvascular disease goes undiagnosed and untreated today.

CorFlow总裁兼首席执行官保罗·米德（PaulMead）评论说，我们很高兴在全球顶级医疗技术投资者财团的支持下完成了这轮重要的融资在我们的MOCA I首次人体试验和广泛的临床前计划中，来自70多名患者的最新数据支持了我们的集体信心，即我们可以改善心脏病发作患者的预后，特别是那些微血管疾病今天未被诊断和治疗的患者。

There is overwhelming evidence now that microvascular conditions are a significant root cause of adverse outcomes in heart attack patients and other cardiovascular conditions. I am grateful that our new investors have the vision to see 'where the puck is going' in this rapidly emerging field.'.

现在有大量证据表明，微血管疾病是心脏病发作患者和其他心血管疾病不良后果的重要根源。我很感激我们的新投资者有远见看到“在这个迅速崛起的领域，冰球将走向何方”。

The MOCA II IDE trial is designed to confirm the CoFl system’s accuracy in diagnosing MVO in high-risk heart attack patients. Led by Principal Investigator Dr. Tim Henry of The Christ Hospital in Cincinnati, Ohio, the trial will recruit several hundred patients undergoing stent implantation due to ST-Elevation Myocardial Infarction (STEMI) and will compare CoFl's proprietary dynamic diagnostic measurement of MVO to post-procedure Contrast Enhanced Cardiac Magnetic Resonance Imaging (CMRI), the current gold standard for detecting MVO.

MOCA II IDE试验旨在确认CoFl系统诊断高危心脏病发作患者MVO的准确性。在俄亥俄州辛辛那提基督医院首席研究员蒂姆·亨利博士的带领下，该试验将招募数百名因ST段抬高心肌梗死（STEMI）而接受支架植入术的患者，并将CoFl专有的MVO动态诊断测量与术后对比增强心脏磁共振成像（CMRI）进行比较，CMRI是目前检测MVO的金标准。

The MOCA II trial leverages the learnings from the company’s First-In-Human MOCA I trial conducted in Switzerland, Latvia and the UK..

MOCA II试验利用了该公司在瑞士、拉脱维亚和英国进行的第一次人体MOCA I试验的经验教训。。

'There is increasing awareness of the impact of MVO on patient outcomes following coronary revascularization. CorFlow has the potential to be the next significant breakthrough in treating coronary artery disease, and Broadview is delighted to be supporting this impressive team and technology,” states David Prim of Broadview Ventures..

。CorFlow有可能成为治疗冠状动脉疾病的下一个重大突破，Broadview很高兴能够支持这一令人印象深刻的团队和技术，”Broadview Ventures的David Prim说道。。

'CorFlow's breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible.' adds Barbara Castellano of Panakes Partners. 'We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.”.

“CorFlow的突破性技术是由临床医生为临床医生设计的，我们很高兴能够支持CorFlow的使命，即生成强大的临床数据，以便尽快为患者提供急需的治疗。”Panakes Partners的芭芭拉·卡斯特拉诺（BarbaraCastellano）补充道我们还致力于支持新兴的微血管疾病领域，这轮超额认购的资金为我们提供了以新的方式和在患者可以受益的新地区应用该技术的选择。”。

The funding will also support a novel adaptive platform therapy trial in Europe evaluating whether localized delivery of therapeutics to the microvasculature immediately following stent implantation can improve outcomes in patients diagnosed with MVO. Led by Dr. Giovanni Luigi De Maria (Oxford University Hospitals Trust, UK) and Professor Colin Berry (University of Glasgow and NHS Golden Jubilee National Hospital, UK), this European RCT will assess the effects of several therapeutic agents with both clinical and imaging measures up to six months..

该资金还将支持在欧洲进行的一项新型适应性平台治疗试验，该试验评估支架植入后立即将治疗药物局部输送至微血管系统是否可以改善诊断为MVO的患者的预后。由Giovanni Luigi De Maria博士（英国牛津大学医院信托基金会）和Colin Berry教授（英国格拉斯哥大学和NHS金禧国立医院）领导，这项欧洲随机对照试验将评估几种治疗剂的临床和影像学效果长达六个月。。

'The improvement in outcomes for heart attack patients has stagnated over many years now and we believe that real-time diagnosis and targeted therapy for MVO has the potential to save the lives of countless patients in the future.' Comments Frederik Groenewegen of 415 Capital. 'We have long been believers in the CorFlow technology and team, and with the support of this first-class investor syndicate we now have the opportunity to collect the clinical data required to establish a new standard of heart attack care.'.

“心脏病发作患者预后的改善多年来一直停滞不前，我们相信MVO的实时诊断和靶向治疗有可能在未来挽救无数患者的生命。”415 Capital的FrederikGroenewegen评论道长期以来，我们一直相信CorFlow技术和团队，在这一一流投资者财团的支持下，我们现在有机会收集建立新的心脏病发作护理标准所需的临床数据。”。

About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with offices in Italy, and founded in 2016 by Dr. Rob Schwartz, Dr. Martin Rothman and Jon Hoem. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists.

关于CorFlow Therapeutics：总部位于瑞士巴尔，在意大利设有办事处，由Rob Schwartz博士、Martin Rothman博士和Jon Hoem于2016年成立。CorFlow立志成为诊断和治疗解决方案的领导者，以恢复人体任何关键需求的健康微血管血流。

Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart..

CorFlow与伯尔尼大学、苏黎世理工大学和苏黎世大学医院的科学家密切合作，在瑞士创新机构（Innosuisse）的资助下，继续探索心脏内外的应用。。

About Microvascular Obstruction (MVO): Often described as the 'last frontier' in the treatment of acute heart attacks, MVO is characterized by blockages in the microvascular coronary arteries, which vary in size down to the circumference of a human hair. Previous research has identified that MVO is one of the most powerful prognostic indicators for future adverse outcomes - for every 1% increase in MVO, there’s a corresponding 14% increase in one-year mortality risk and 8% increase in hospitalization due to heart failure..

关于微血管阻塞（MVO）：通常被描述为治疗急性心脏病发作的“最后前沿”，MVO的特征是微血管冠状动脉阻塞，其大小不等，直至头发的周长。先前的研究已经确定，MVO是未来不良后果最有力的预后指标之一-MVO每增加1%，一年死亡率风险就会相应增加14%，心力衰竭住院率就会增加8%。。